Enanta Pharmaceuticals (FRA:9EP) Cyclically Adjusted Book per Share: € (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:9EP Enanta Pharmaceuticals Inc FRA:9EP
55 GF Score
Price €10.60
GF Value €6.67
! 6 Warning Signs
View Full Analysis

What is Enanta Pharmaceuticals Cyclically Adjusted Book per Share?

Enanta Pharmaceuticals FRA:9EP -1.85% 55 Cyclically Adjusted Book per Share is € as of Jun. 2026. GuruFocus rates FRA:9EP with a GF Score™ of 55/100 and a GF Value™ of €6.67. The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Enanta Pharmaceuticals's adjusted book value per share for the three months ended in Jun. 2026 was €3.036. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is for the trailing ten years ended in Jun. 2026.

During the past 12 months, Enanta Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was -4.50% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 1.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Enanta Pharmaceuticals was 8.00% per year. The lowest was 1.50% per year. And the median was 4.75% per year.

As of today (2026-09-21), Enanta Pharmaceuticals's current stock price is €10.60. Enanta Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was . Enanta Pharmaceuticals's Cyclically Adjusted PB Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Enanta Pharmaceuticals was 6.25. The lowest was 0.24. And the median was 0.75.


Enanta Pharmaceuticals  (FRA:9EP) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Enanta Pharmaceuticals was 6.25. The lowest was 0.24. And the median was 0.75.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Enanta Pharmaceuticals Cyclically Adjusted Book per Share Related Terms


Enanta Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Enanta Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enanta Pharmaceuticals Cyclically Adjusted Book per Share Chart

Enanta Pharmaceuticals Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Enanta Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

FRA:9EP vs LXEO, XFOR, GALT: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Enanta Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enanta Pharmaceuticals Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enanta Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Enanta Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


FRA:9EP
55GF Score
Enanta Pharmaceuticals Inc FRA:9EP
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Enanta Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Enanta Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=3.036/333.9520*333.9520
=3.036

Current CPI (Jun. 2026) = 333.9520.

Enanta Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201609 12.618 241.428 17.454
201612 13.353 241.432 18.470
201703 13.053 243.801 17.880
201706 11.981 244.955 16.334
201709 13.346 246.819 18.057
201712 13.811 246.524 18.709
201803 14.075 249.554 18.835
201806 15.966 251.989 21.159
201809 17.476 252.439 23.119
201812 19.212 251.233 25.538
201903 19.751 254.202 25.947
201906 19.992 256.143 26.065
201909 21.531 256.759 28.004
201912 21.689 256.974 28.186
202003 22.161 258.115 28.672
202006 21.319 257.797 27.617
202009 19.351 260.280 24.828
202012 18.340 260.474 23.514
202103 18.380 264.877 23.173
202106 17.433 271.696 21.428
202109 17.030 274.310 20.733
202112 16.483 278.802 19.744
202203 15.631 287.504 18.156
202206 15.605 296.311 17.587
202209 15.776 296.808 17.750
202212 13.497 296.797 15.187
202303 11.779 301.836 13.032
202306 10.353 305.109 11.332
202309 9.721 307.789 10.547
202312 8.211 306.746 8.939
202403 7.262 312.332 7.765
202406 6.560 314.175 6.973
202409 5.446 315.301 5.768
202412 5.062 315.605 5.356
202503 4.051 319.799 4.230
202506 3.159 322.561 3.271
202509 2.575 324.800 2.648
202512 3.714 324.054 3.827
202603 3.482 330.213 3.521
202606 3.036 333.952 3.036

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of € mean?
Enanta Pharmaceuticals (FRA:9EP) has a Cyclically Adjusted Book per Share of € as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Enanta Pharmaceuticals and its competitors.
Is Enanta Pharmaceuticals' Cyclically Adjusted Book per Share too high?
Enanta Pharmaceuticals' current Cyclically Adjusted Book per Share is €. Overall, Enanta Pharmaceuticals has a GF Score™ of 55/100, reflecting its overall financial health beyond just this single metric.
How does Enanta Pharmaceuticals' Cyclically Adjusted Book per Share compare to LXEO and XFOR?
Enanta Pharmaceuticals' Cyclically Adjusted Book per Share of € can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Enanta Pharmaceuticals and its competitors. Enanta Pharmaceuticals's current Cyclically Adjusted Book per Share is €. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enanta Pharmaceuticals stock overvalued right now?
Enanta Pharmaceuticals (FRA:9EP) has a current Cyclically Adjusted Book per Share of €. The stock's GF Value™ is €6.67, compared to a current price of €10.60 — trading 58.9% above its estimated fair value. The current Cyclically Adjusted Book per Share is €. Enanta Pharmaceuticals' overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Enanta Pharmaceuticals (FRA:9EP), the current Cyclically Adjusted Book per Share is € as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Enanta Pharmaceuticals (FRA:9EP) Overvalued in 2026?

Based on GuruFocus' analysis, Enanta Pharmaceuticals stock appears to be overvalued. The current stock price of €10.60 is trading 58.9% above its estimated GF Value™ of €6.67.

Key valuation signals for FRA:9EP:

  • Cyclically Adjusted Book per Share:
  • GF Value™: €6.67 vs. price of €10.60 (58.9% above fair value)
  • GF Score™: 55/100 with 6 warning signs

No single metric tells the full story. See the FRA:9EP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Enanta Pharmaceuticals Business Description

Other Exchanges ENTA:USA
Address 4 Kingsbury Avenue, Watertown, MA, USA, 02472
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
55GF Score

Get the complete analysis for FRA:9EP

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€10.60
Price
€6.67
GF Value